Details for New Drug Application (NDA): 061866
✉ Email this page to a colleague
NDA 061866 describes ANSPOR, which is a drug marketed by Glaxosmithkline and is included in two NDAs. Additional details are available on the ANSPOR profile page.
The generic ingredient in ANSPOR is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
The generic ingredient in ANSPOR is cephradine. There are ten drug master file entries for this compound. Additional details are available on the cephradine profile page.
Summary for 061866
| Tradename: | ANSPOR |
| Applicant: | Glaxosmithkline |
| Ingredient: | cephradine |
| Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 061866
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | 125MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Profile for product number 002
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | FOR SUSPENSION;ORAL | Strength | 250MG/5ML | ||||
| Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
